South Korea
· Delayed Price · Currency is KRW Clinomics Statistics
Total Valuation
Clinomics has a market cap or net worth of KRW 25.70 billion. The enterprise value is 55.47 billion.
| Market Cap | 25.70B |
| Enterprise Value | 55.47B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Clinomics has 38.88 million shares outstanding. The number of shares has increased by 69.22% in one year.
| Shares Outstanding | 38.88M |
| Shares Change (YoY) | +69.22% |
| Shares Change (QoQ) | +14.19% |
| Owned by Insiders (%) | 6.93% |
| Owned by Institutions (%) | 3.36% |
| Float | 30.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.31 |
| PB Ratio | 0.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.67 |
| EV / Sales | 5.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.32 |
Financial Position
The company has a current ratio of 0.41, with a Debt / Equity ratio of 0.81.
| Current Ratio | 0.41 |
| Quick Ratio | 0.16 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.82 |
| Interest Coverage | -8.83 |
Financial Efficiency
Return on equity (ROE) is -77.49% and return on invested capital (ROIC) is -22.14%.
| Return on Equity (ROE) | -77.49% |
| Return on Assets (ROA) | -16.91% |
| Return on Capital (ROIC) | -22.14% |
| Revenue Per Employee | 130.06M |
| Profits Per Employee | -442.86M |
| Employee Count | 75 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 3.37 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -70.40% |
| 50-Day Moving Average | 1,009.64 |
| 200-Day Moving Average | 1,738.98 |
| Relative Strength Index (RSI) | 32.10 |
| Average Volume (20 Days) | 1,346,758 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Clinomics had revenue of KRW 9.75 billion and -33.21 billion in losses. Loss per share was -973.53.
| Revenue | 9.75B |
| Gross Profit | 474.64M |
| Operating Income | -27.06B |
| Pretax Income | -33.40B |
| Net Income | -33.21B |
| EBITDA | -23.10B |
| EBIT | -27.06B |
| Loss Per Share | -973.53 |
Balance Sheet
The company has 6.63 billion in cash and 36.15 billion in debt, giving a net cash position of -29.52 billion or -759.12 per share.
| Cash & Cash Equivalents | 6.63B |
| Total Debt | 36.15B |
| Net Cash | -29.52B |
| Net Cash Per Share | -759.12 |
| Equity (Book Value) | 44.57B |
| Book Value Per Share | 1,139.63 |
| Working Capital | -30.01B |
Cash Flow
In the last 12 months, operating cash flow was -9.78 billion and capital expenditures -3.06 billion, giving a free cash flow of -12.84 billion.
| Operating Cash Flow | -9.78B |
| Capital Expenditures | -3.06B |
| Free Cash Flow | -12.84B |
| FCF Per Share | -330.19 |
Margins
| Gross Margin | 4.87% |
| Operating Margin | -277.37% |
| Pretax Margin | -342.42% |
| Profit Margin | n/a |
| EBITDA Margin | -236.86% |
| EBIT Margin | -277.37% |
| FCF Margin | -131.62% |
Dividends & Yields
Clinomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -69.22% |
| Shareholder Yield | -69.22% |
| Earnings Yield | -147.28% |
| FCF Yield | -49.95% |
Stock Splits
The last stock split was on August 10, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Aug 10, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Clinomics has an Altman Z-Score of -1.27. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.27 |
| Piotroski F-Score | n/a |